Recommendations for hormone therapy in hysterectomized women: importance of new data in clinical management

References

• Sarrel PM, Njike VY, Vinante V, Katz DL. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am J Public Health 2013;103(9):1583-8
   PubMed Web of Science ®Google Scholar
• Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013;310(13):1353-68
   PubMed Web of Science ®Google Scholar
• LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305(13):1305-14
   PubMed Web of Science ®Google Scholar
• Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345:e6409
   PubMedGoogle Scholar
• Harman SM, Black DM, Naftolin F, et al. Arterial Imaging Outcomes and Cardiovascular Risk Factors in Recently Menopausal Women in The Kronos Early Estrogen Prevention Study (KEEPS): a Randomized Controlled Trial. Ann Intern Med 2014;161(4):249-60
   PubMed Web of Science ®Google Scholar
• Simon JA. What if the Women’s Health Initiative had used transdermal estradiol and oral progesterone instead? Menopause 2014;21(7):769-83
   PubMedGoogle Scholar
• Lobo RA. Where are we 10 years after the Women’s Health Initiative? J Clin Endocrinol Metab 2013;98(5):1771-80
   PubMed Web of Science ®Google Scholar
• Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol 2012;120(3):595-603
   PubMed Web of Science ®Google Scholar
• Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291(1):47-53
   PubMed Web of Science ®Google Scholar
• Utian WH. A decade post WHI, menopausal hormone therapy comes full circle–need for independent commission. Climacteric 2012;15(4):320-5
   PubMed Web of Science ®Google Scholar
• Buist DS, Newton KM, Miglioretti DL, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol 2004;104(5 Pt 1):1042-50
   PubMedGoogle Scholar
• Steinkellner AR, Denison SE, Eldridge SL, et al. A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women’s Health Initiative. Menopause 2012;19(6):616-21
   PubMed Web of Science ®Google Scholar
• Boothby LA, Doering PL, Kipersztok S. Bioidentical hormone therapy: a review. Menopause 2004;11(3):356-67
   PubMed Web of Science ®Google Scholar
• Iftikhar S, Shuster LT, Johnson RE, et al. Use of bioidentical compounded hormones for menopausal concerns: cross-sectional survey in an academic menopause center. J Womens Health (Larchmt) 2011;20(4):559-65
   PubMed Web of Science ®Google Scholar
• The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012;19(3):257-71
   PubMed Web of Science ®Google Scholar
• Compounded bioidentical menopausal hormone therapy. Fertil Steril 2012;98(2):308-12
   PubMed Web of Science ®Google Scholar
• Merrill RM. Hysterectomy surveillance in the United States, 1997 through 2005. Med Sci Monit 2008;14(1):CR24-31
   PubMed Web of Science ®Google Scholar
• Asante A, Whiteman MK, Kulkarni A, et al. Elective oophorectomy in the United States: trends and in-hospital complications, 1998-2006. Obstet Gynecol 2010;116(5):1088-95
   PubMedGoogle Scholar
• Whiteman MK, Hillis SD, Jamieson DJ, et al. Inpatient hysterectomy surveillance in the United States, 2000-2004. Am J Obstet Gynecol 2008;198(1):34 e31-7
   Google Scholar
• Harmanli O, Shinnick J, Jones K, St Marie P. Obstetrician-gynecologists’ opinions on elective bilateral oophorectomy at the time of hysterectomy in the United States: a nationwide survey. Menopause 2014;21(4):355-60
   PubMedGoogle Scholar
• Farquhar CM, Sadler L, Harvey SA, Stewart AW. The association of hysterectomy and menopause: a prospective cohort study. BJOG 2005;112(7):956-62
   PubMedGoogle Scholar
• Hendrix SL. Bilateral oophorectomy and premature menopause. Am J Med 2005;118(Suppl 12B):131-5
   PubMedGoogle Scholar
• Read MD, Edey KA, Hapeshi J, Foy C. The age of ovarian failure following premenopausal hysterectomy with ovarian conservation. Menopause Int 2010;16(2):56-9
   PubMedGoogle Scholar
• Parker WH, Feskanich D, Broder MS, et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol 2013;121(4):709-16
   PubMed Web of Science ®Google Scholar
• Rosenberg L, Hennekens CH, Rosner B, et al. Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol 1981;139(1):47-51
   PubMedGoogle Scholar
• Howard BV, Kuller L, Langer R, et al. Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Women’s Health Initiative Observational Study. Circulation 2005;111(12):1462-70
   PubMedGoogle Scholar
• Madalinska JB, van Beurden M, Bleiker EM, et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 2006;24(22):3576-82
   PubMedGoogle Scholar
• Rocca WA, Grossardt BR, Shuster LT. Oophorectomy, menopause, estrogen treatment, and cognitive aging: clinical evidence for a window of opportunity. Brain Res 2011;1379:188-98
   PubMed Web of Science ®Google Scholar
• Parker WH, Broder MS, Liu Z, et al. Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 2005;106(2):219-26
   PubMedGoogle Scholar
• Gierach GL, Pfeiffer RM, Patel DA, et al. Long-term overall and disease-specific mortality associated with benign gynecologic surgery performed at different ages. Menopause 2014;21(6):592-601
   PubMed Web of Science ®Google Scholar
• Rocca WA, Grossardt BR, de Andrade M, et al. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 2006;7(10):821-8
   PubMed Web of Science ®Google Scholar
• Vajaranant TS, Grossardt BR, Maki PM, et al. Risk of glaucoma after early bilateral oophorectomy. Menopause 2014;21(4):391-8
   PubMed Web of Science ®Google Scholar
• Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 2009;16(1):15-23
   PubMed Web of Science ®Google Scholar
• Rocca WA, Grossardt BR, Maraganore DM. The Long-Term Effects of Oophorectomy on Cognitive and Motor Aging Are Age Dependent. Neurodegener Dis 2008;5:257-60
   PubMed Web of Science ®Google Scholar
• Bove R, Secor E, Chibnik LB, et al. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology 2014;82(3):222-9
   PubMed Web of Science ®Google Scholar
• Rocca WA, Grossardt BR, Geda YE, et al. Long-term risk of depressive and anxiety symptoms after early bilateral oophorectomy. Menopause 2008;15(6):1050-9
   PubMed Web of Science ®Google Scholar
• Dennerstein L, Koochaki P, Barton I, Graziottin A. Hypoactive sexual desire disorder in menopausal women: a survey of Western European women. J Sex Med 2006;3(2):212-22
   PubMed Web of Science ®Google Scholar
• Shuster LT, Gostout BS, Grossardt BR, Rocca WA. Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int 2008;14(3):111-16
   PubMedGoogle Scholar
• Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007;69(11):1074-83
   PubMed Web of Science ®Google Scholar
• Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008;70(3):200-9
   PubMed Web of Science ®Google Scholar
• Zhou G, Liu J, Sun F, et al. Cognitive functioning in elderly women who underwent unilateral oophorectomy before menopause. Int J Neurosci 2011;121(4):196-200
   PubMed Web of Science ®Google Scholar
• Laughlin-Tommaso SK, Stewart EA, Grossardt BR, et al. Incidence, time trends, laterality, indications, and pathological findings of unilateral oophorectomy before menopause. Menopause 2014;21(5):442-9
   PubMedGoogle Scholar
• Brown DN. Ovary and unilateral oophorectomy: is having one the same as having two? Menopause 2014;21(5):435-6
   PubMedGoogle Scholar
• Beral V, Reeves G, Bull D, Green J. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 2011;103(4):296-305
   PubMedGoogle Scholar
• Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332(24):1589-93
   PubMed Web of Science ®Google Scholar
• Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses’ Health Study. Am J Epidemiol 2000;152(10):950-64
   PubMed Web of Science ®Google Scholar
• Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006;166(9):1027-32
   PubMedGoogle Scholar
• de Villiers TJ, Pines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013;16(3):316-37
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009;360(6):573-87
   PubMed Web of Science ®Google Scholar
• Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295(14):1647-57
   PubMed Web of Science ®Google Scholar
• Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362(9382):419-27
   PubMed Web of Science ®Google Scholar
• Stahlberg C, Pedersen AT, Lynge E, et al. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 2004;109(5):721-7
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Riboli E, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005;114(3):448-54
   PubMed Web of Science ®Google Scholar
• Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 1999;130(4 Pt 1):262-9
   PubMedGoogle Scholar
• Guidelines for counseling postmenopausal women about preventive hormone therapy. American College of Physicians. Ann Intern Med 1992;117(12):1038-41
   PubMed Web of Science ®Google Scholar
• Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117(12):1016-37
   PubMed Web of Science ®Google Scholar
• Harman SM, Vittinghoff E, Brinton EA, et al. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. Am J Med 2011;124(3):199-205
   PubMed Web of Science ®Google Scholar
• Choi SD, Steinberg EM, Lee HH, Naftolin F. The Timing Hypothesis remains a valid explanation of differential cardioprotective effects of menopausal hormone treatment. Menopause 2011;18(2):230-6
   PubMedGoogle Scholar
• Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356(25):2591-602
   PubMed Web of Science ®Google Scholar
• Maki PM. Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies. Menopause 2013;20(6):695-709
   PubMed Web of Science ®Google Scholar
• Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998;279(9):688-95
   PubMed Web of Science ®Google Scholar
• LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 2001;285(11):1489-99
   PubMed Web of Science ®Google Scholar
• Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289(20):2651-62
   PubMed Web of Science ®Google Scholar
• Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: women’s Health Initiative Memory Study. JAMA 2004;291(24):2947-58
   PubMed Web of Science ®Google Scholar
• Resnick SM, Maki PM, Rapp SR, et al. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab 2006;91(5):1802-10
   PubMed Web of Science ®Google Scholar
• Maki PM, Gast MJ, Vieweg AJ, et al. Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial. Neurology 2007;69(13):1322-30
   PubMed Web of Science ®Google Scholar
• Binder EF, Schechtman KB, Birge SJ, et al. Effects of hormone replacement therapy on cognitive performance in elderly women. Maturitas 2001;38(2):137-46
   PubMedGoogle Scholar
• Utian WH, Woods NF. Impact of hormone therapy on quality of life after menopause. Menopause 2013;20(10):1098-105
   PubMedGoogle Scholar
• Pines A, Sturdee DW, MacLennan AH. Quality of life and the role of menopausal hormone therapy. Climacteric 2012;15(3):213-16
   PubMed Web of Science ®Google Scholar
• National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med 2005;142(12 Pt 1):1003-13
   PubMedGoogle Scholar
• de Villiers TJ, Gass ML, Haines CJ, et al. Global Consensus Statement on menopausal hormone therapy. Maturitas 2013;74(4):391-2
   PubMed Web of Science ®Google Scholar
• Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95(7 Suppl 1):s1-s66
   PubMed Web of Science ®Google Scholar
• Prior JC, Hitchcock CL. Progesterone for hot flush and night sweat treatment–effectiveness for severe vasomotor symptoms and lack of withdrawal rebound. Gynecol Endocrinol 2012;28(Suppl 2):7-11
   PubMedGoogle Scholar
• Benster B, Carey A, Wadsworth F, et al. A double-blind placebo-controlled study to evaluate the effect of progestelle progesterone cream on postmenopausal women. Menopause Int 2009;15(2):63-9
   PubMedGoogle Scholar
• Hachul H, Bittencourt LR, Andersen ML, et al. Effects of hormone therapy with estrogen and/or progesterone on sleep pattern in postmenopausal women. Int J Gynaecol Obstet 2008;103(3):207-12
   PubMed Web of Science ®Google Scholar
• Sood R, Shuster L, Smith R, et al. Counseling postmenopausal women about bioidentical hormones: ten discussion points for practicing physicians. J Am Board Fam Med 2011;24(2):202-10
   PubMedGoogle Scholar
• Vongpatanasin W, Tuncel M, Wang Z, et al. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol 2003;41(8):1358-63
   PubMedGoogle Scholar
• Goodman MP. Are all estrogens created equal? A review of oral vs. transdermal therapy. J Womens Health (Larchmt) 2012;21(2):161-9
   PubMed Web of Science ®Google Scholar
• Simon JA. What’s new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone. Climacteric 2012;15(Suppl 1):3-10
   PubMed Web of Science ®Google Scholar
• ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstet Gynecol 2014;123(1):202-16
   PubMed Web of Science ®Google Scholar
• Aslan E, Bagis T, Kilicdag EB, et al. How best is to discontinue postmenopausal hormone therapy: immediate or tapered? Maturitas 2007;56(1):78-83
   PubMedGoogle Scholar
• Grady D, Ettinger B, Tosteson AN, et al. Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstet Gynecol 2003;102(6):1233-9
   PubMedGoogle Scholar
• Ockene JK, Barad DH, Cochrane BB, et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA 2005;294(2):183-93
   PubMed Web of Science ®Google Scholar
• Panay N, Hamoda H, Arya R, Savvas M. The 2013 British Menopause Society & Women’s Health Concern recommendations on hormone replacement therapy. Menopause Int 2013;19(2):59-68
   PubMedGoogle Scholar
• Sood R, Faubion SS, Kuhle CL, et al. Prescribing menopausal hormone therapy: an evidence-based approach. Int J Womens Health 2014;6:47-57. eCollection 2014
   PubMedGoogle Scholar